Document Type
Article
Publication Date
7-16-2018
Abstract
Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease. Its mechanism is still not clear. Majority of research focused on the central nervous system (CNS) changes, while few studies emphasize on peripheral immune system modulation. Our study aimed to investigate the regulation of the peripheral immune system and its relationship to the severity of the disease after treatment in an AD model of APPswe/PSEN1dE9 transgenic (APP/PS1 Tg) mice. APP/PS1 Tg mice (8 months old) were treated with the ROCK-II inhibitor 1-(5-isoquinolinesulfonyl)-homo-piperazine (Fasudil) (intraperitoneal (i.p.) injections, 25 mg/kg/day), bone marrow stromal cells (BMSCs; caudal vein injections, 1 × 10
Recommended Citation
Yu, Jiezhong; Yan, Yuqing; Gu, Qingfang; Kumar, Gajendra; Yu, Hongqiang; Zhao, Yijin; Liu, Chunyun; Gao, Ye; Chai, Zhi; Chumber, Jasleen; Xiao, Bao-Guo; Zhang, Guang-Xian; Zhang, Han-Ting; Jiang, Yuqiang; and Ma, Cun-Gen, "Fasudil in Combination With Bone Marrow Stromal Cells (BMSCs) Attenuates Alzheimer's Disease-Related Changes Through the Regulation of the Peripheral Immune System." (2018). Department of Neurology Faculty Papers. Paper 161.
https://jdc.jefferson.edu/neurologyfp/161
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
30061826
Language
English
Comments
This article has been peer reviewed. It is the author’s final published version in Frontiers in Aging Neuroscience, Volume 10, Issue 3, July 2018, Article number 216.
The published version is available at https://doi.org/10.3389/fnagi.2018.00216. Copyright © Yu et al.